10-K: Delcath Systems Reports Strong Revenue Growth, Advances Liver Cancer Therapies

Delcath Systems, Inc. reported a significant increase in revenue for 2025, driven by the commercial expansion of HEPZATO KIT in the US and CHEMOSAT in Europe, alongside positive clinical trial results for combination therapies.

Summary

• Net income was $2.7 million in 2025, a significant improvement from a net loss of $26.4 million in 2024.
• Total revenue increased to $85.2 million in 2025 from $37.2 million in 2024, driven by the commercial expansion of HEPZATO KIT in the United States and CHEMOSAT in Europe.
• HEPZATO KIT, approved by the FDA in August 2023 for uveal melanoma with unresectable hepatic metastases, saw its first commercial use in January 2024 and expanded to 25 active sites by December 31, 2025.
• CHEMOSAT received Medical Device Regulation (MDR) certification in Europe in February 2022 and is currently available in 22 cancer centers across Europe.
• Positive results from the Phase 2 CHOPIN trial for CHEMOSAT combined with immune checkpoint inhibitors (ipilimumab and nivolumab) in metastatic uveal melanoma (mUM) showed significantly improved one-year progression-free survival (54.7% vs 15.8% for PHP alone), median Overall Survival (23.1 months vs 19.6 months), median Progression Free Survival (12.8 months vs 8.3 months), and Objective Response Rate (76.3% vs 39.5%).
• The FDA cleared Investigational New Drug (IND) applications for Phase 2 clinical trials of HEPZATO in liver-dominant metastatic colorectal cancer (mCRC) in December 2024 and HER2-negative metastatic breast cancer (mBC) in April 2025.
• Patient enrollment for the mCRC trial began in the third quarter of 2025 across more than 20 sites in the United States and Europe.
• Patient enrollment for the mBC trial is expected to begin in the first quarter of 2026 across more than 15 sites in the United States and Europe.
• Cash and cash equivalents increased to $43.5 million as of December 31, 2025, from $32.4 million as of December 31, 2024.
• A share repurchase program of up to $25 million was authorized in November 2025, with approximately $6.0 million repurchased and retired by year-end.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, reflecting significant revenue growth, a return to profitability, and highly encouraging clinical trial results for combination therapies, which could drive future market expansion.

Positives

• Total revenue increased significantly by 129% to $85.2 million in 2025 from $37.2 million in 2024, indicating strong commercial traction.
• Achieved a net income of $2.7 million in 2025, a substantial turnaround from a net loss of $26.4 million in 2024.
• Gross profit increased by 137% to $73.4 million in 2025 from $31.0 million in 2024.
• Net cash provided by operating activities was $22.5 million in 2025, compared to net cash used of $18.7 million in 2024, demonstrating improved operational efficiency and cash generation.
• Positive results from the Phase 2 CHOPIN trial for CHEMOSAT in combination with immune checkpoint inhibitors for mUM showed statistically significant improvements in one-year progression-free survival (54.7% vs 15.8%), median Overall Survival (23.1 months vs 19.6 months), median Progression Free Survival (12.8 months vs 8.3 months), and Objective Response Rate (76.3% vs 39.5%).
• FDA clearance for Phase 2 clinical trials of HEPZATO in metastatic colorectal cancer (mCRC) and metastatic breast cancer (mBC) expands potential indications and market opportunities.
• HEPZATO KIT's first commercial use in January 2024 and expansion to 25 active sites in the US by December 31, 2025, indicates successful initial market penetration.
• CMS established a permanent, product-specific J-Code (J9248) for HEPZATO, effective April 1, 2024, and granted New Technology Add-on Payment (NTAP) status, effective October 1, 2024, enhancing reimbursement and market access.
• Entry into a National Drug Rebate Agreement (NDRA) with CMS and a Pharmaceutical Pricing Agreement (PPA) with the Public Health Service, along with a master agreement with the U.S. Department of Veterans Affairs (VA), further expands market access.
• The Board authorized a $25 million share repurchase program in November 2025, with $6.0 million already executed, signaling confidence in the company's valuation.

Negatives

• Research and development expenses increased significantly to $29.2 million in 2025 from $13.9 million in 2024, reflecting increased costs for clinical trials.
• Selling, general and administrative expenses increased to $43.5 million in 2025 from $29.6 million in 2024, due to continued commercial expansion activities and personnel costs.
• The company has a substantial accumulated deficit of $528.8 million as of December 31, 2025, despite achieving net income in the current year.
• The One Big Beautiful Bill Act (OBBBA) and other healthcare reforms are anticipated to reduce the number of Americans with health insurance and Medicaid spending, potentially impacting demand and pricing for products.
• The BIOSECURE Act, signed into law in December 2025, may restrict the ability to work with certain Chinese biotechnology manufacturing companies if contracting with the U.S. government.
• The market price of common stock has been volatile, fluctuating between a high of $18.10 and a low of $8.19 in 2025.

Risks

• The company may need additional capital to maintain operations, further commercialize CHEMOSAT and HEPZATO, or conduct future product development, including clinical trials.
• Limited experience as a commercial company and generating revenue from product sales; if commercialization is unsuccessful, the company may never be profitable or obtain sustainable profitability.
• Inability to maintain or enter into acceptable arrangements for the supply of melphalan and other critical components of HEPZATO and CHEMOSAT, impacting commercialization and future clinical trials.
• Inability to successfully manufacture CHEMOSAT and HEPZATO would impair the ability to develop and commercialize the system.
• The company does not have written contracts with all suppliers for the manufacture of components for CHEMOSAT and HEPZATO.
• Unsuccessful commercialization of CHEMOSAT and HEPZATO due to inadequate infrastructure or an ineffective commercialization strategy.
• The development and approval process in the United States and abroad could take many years, require substantial resources, and may never lead to the approval of product candidates.
• The ability to market HEPZATO is limited to those uses that are approved.
• If future clinical trials are unsuccessful, significantly delayed, or not completed, the company may not be able to market HEPZATO for other indications.
• Commercialization of CHEMOSAT in the European Union will be significantly limited if physicians are unable or unwilling to obtain melphalan separately for use with CHEMOSAT.
• Continued reliance on third parties to conduct certain elements of clinical trials; if these third parties do not perform their obligations, necessary regulatory approvals may not be obtained.
• Purchasers of CHEMOSAT in Europe may not receive third-party reimbursement or such reimbursement may be inadequate, hindering commercialization.
• CHEMOSAT and HEPZATO may not achieve sufficient acceptance by the medical community to sustain the business.
• The company may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws, potentially leading to substantial penalties for non-compliance.
• Stringent and evolving United States and foreign laws, regulations, rules, contractual obligations, industry standards, policies, and other obligations related to information privacy and security, with actual or perceived failure to comply leading to regulatory investigations, litigation, fines, and business disruptions.
• Changes in healthcare law and implementing regulations, including government restrictions on pricing and reimbursement, as well as healthcare policy and other healthcare payor cost-containment initiatives, may have a material adverse effect.
• Consolidation in the healthcare industry could lead to demands for price concessions.
• Intellectual property rights may not provide adequate protection, permitting third parties to compete more effectively.
• The company has not and may not be able to adequately protect its intellectual property rights throughout the world.
• Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements, and patent protection could be reduced or eliminated for non-compliance.
• The market price of common stock has been, and may continue to be, volatile and fluctuate significantly, which could result in substantial losses for investors.
• Volatility in trading price and volume may lead to significant costs from class action securities litigation.
• Sales of a substantial number of shares of common stock in the public market, or the perception that such sales may occur, could adversely affect the market price and impair the ability to raise additional equity capital.
• The loss of key personnel could adversely affect the business.
• The business could be adversely affected by economic downturns, inflation, increases in interest rates, natural disasters, public health crises, political crises, global geopolitical conflicts, trade wars, or other macroeconomic conditions.
• Environmental, social, and governance matters and any related reporting obligations may impact the business.
• Reliance on the proper function, availability, and security of information technology systems; a cyber-attack or other breach could have a material adverse effect.
• Significant ongoing costs as a public company, with management devoting substantial time to compliance initiatives.
• As a smaller reporting company, the election to comply with reduced public company reporting requirements could make common stock less attractive to investors.

Future Outlook

The company expects research and development expenses to increase for the foreseeable future due to ongoing Phase 2 clinical trials for metastatic colorectal cancer (mCRC) and metastatic breast cancer (mBC). These trials are anticipated to support eventual regulatory submissions for label expansion in the United States and increased clinical adoption and reimbursement in various jurisdictions. The primary endpoint (hepatic progression-free survival) for the mCRC trial is expected by the end of 2027, with Overall Survival (a secondary endpoint) in 2028. For the mBC trial, hepatic progression-free survival is anticipated by the end of 2028, and Overall Survival in 2029. The company believes its current cash, cash equivalents, and investments will be sufficient to support current operations for at least 12 months from the issuance of the consolidated financial statements.

Management Comments

• We have sufficient raw material and component constituent parts of the HEPZATO KIT to meet anticipated demand and we intend to manage supply chain risk through stockpiled inventory and contracting with multiple suppliers for critical components.
• We believe that our current cash on hand, cash equivalents and investments will be sufficient to support our current operations through at least 12 months from the issuance of the consolidated financial statements included in this Annual Report on Form 10-K.

Industry Context

StockSavvy.ai notes that Delcath Systems operates in the highly competitive interventional oncology space, targeting significant unmet medical needs in liver cancers. The positive Phase 2 CHOPIN trial results for CHEMOSAT in combination with immune checkpoint inhibitors are particularly noteworthy, as combination therapies are a growing trend in oncology, aiming to improve efficacy and overcome resistance. The company's focus on expanding indications for HEPZATO into metastatic colorectal cancer and metastatic breast cancer aligns with broader industry efforts to leverage existing therapies for new patient populations, especially in liver-dominant metastatic settings where treatment options are often limited. The regulatory approvals and reimbursement advancements (J-Code, NTAP) for HEPZATO in the US are critical for market access, reflecting a positive trend for innovative therapies that demonstrate clinical benefit.

Comparison to Industry Standards

• The FOCUS trial's Objective Response Rate (ORR) of 36.3% for HEPZATO in metastatic uveal melanoma (mUM) was statistically significantly better than the pooled ORR estimate of 5.5% in the historical control group, indicating strong efficacy compared to traditional approaches.
• The CHOPIN trial's combination group (CHEMOSAT + ipilimumab + nivolumab) achieved a one-year progression-free survival rate of 54.7% versus 15.8% for PHP alone, and an ORR of 76.3% versus 39.5%. This demonstrates superior efficacy compared to monotherapy, aligning with the industry trend of enhanced outcomes through combination regimens.
• KIMMTRAK (tebentafusp-tebn) from Immunocore Holdings plc is the first FDA-approved systemic therapy for HLA-A*02:01-positive mUM patients (approximately 45% of mUM patients). HEPZATO is approved for all mUM patients and is the only approved drug for the remaining 55%, positioning it uniquely in the market.
• Competitors like Boston Scientific Corporation, the Covidien Products division of Medtronic plc, Merit Medical Systems, Inc., Varian Medical Systems, Inc., Sirtex Medical Limited, and AngioDynamics, Inc. offer local regional procedures (trans-arterial chemoembolization, radioembolization), but these are not approved for mUM, highlighting HEPZATO's specific regulatory advantage.
• IDEAYA Biosciences (developing darovasertib in combination with crizotinib) and Replimune Group (investigating RP2, an oncolytic immunotherapy) are currently developing mUM therapies, but neither has received approval, indicating Delcath's current lead in approved treatments for this indication.

Corporate Governance

Legal Proceedings

• The company reached a final settlement in the medac matter, agreeing to pay medac either a royalty on CHEMOSAT sales over a defined minimum for five years or until a maximum payment is reached, or a minimum annual payment of $0.2 million. The estimated remaining fair value of the settlement is $0.9 million as of December 31, 2025.

Stakeholder Impact

• Shareholders: Positive impact from the return to profitability, significant revenue growth, positive clinical trial results, and the initiation of a share repurchase program. Potential for future dilution from additional equity raises under the shelf registration statement.
• Patients: Improved treatment options for metastatic uveal melanoma with HEPZATO KIT, and potential for new treatments for metastatic colorectal cancer and metastatic breast cancer through ongoing clinical trials.
• Employees: Continued growth and expansion of clinical and commercial teams, with stock-based compensation as part of incentive programs. Subject to new AI governance framework and cybersecurity training.
• Healthcare Providers/Cancer Centers: Increased access to HEPZATO KIT with 25 active sites and established reimbursement codes (J-Code, NTAP) in the US. CHEMOSAT available in 22 European centers.
• Suppliers: Continued demand for melphalan and other critical components, but also risk from reliance on single-source suppliers and potential impacts from trade regulations.
• Regulatory Bodies: Ongoing compliance requirements for FDA and European regulatory agencies, including REMS for HEPZATO and MDR certification for CHEMOSAT.

Next Steps

• Continue commercialization of HEPZATO KIT in the United States, expanding active treatment sites and patient referrals.
• Expand commercialization of CHEMOSAT in Europe, focusing on increasing reimbursement mechanisms in priority markets.
• Conduct the Phase 2 clinical trial for HEPZATO in liver-dominant metastatic colorectal cancer (mCRC), with patient enrollment ongoing and primary endpoint readout anticipated by the end of 2027.
• Initiate the Phase 2 clinical trial for HEPZATO in liver-dominant HER2-negative metastatic breast cancer (mBC), with patient enrollment expected to begin in Q1 2026.
• Manage supply chain risk for critical components, including melphalan, through stockpiled inventory and contracting with multiple suppliers.
• Monitor and comply with evolving healthcare laws and regulations, including those related to pricing and reimbursement, such as the Inflation Reduction Act and the One Big Beautiful Bill Act.
• Implement and ensure compliance with the extensive Risk Evaluation and Mitigation Strategy (REMS) program for HEPZATO.
• Evaluate and consider different strategic alternatives, such as acquiring businesses, technologies, or products, or entering into business combinations.
• Continue to attract, hire, and retain qualified scientific, technical, commercial, and administrative personnel.
• Maintain and enhance information technology systems and cybersecurity measures to protect sensitive information and operations.

Key Dates

Recommendation

The company has demonstrated a significant financial turnaround, moving from a substantial net loss to profitability, coupled with impressive revenue growth driven by successful commercialization of HEPZATO KIT and CHEMOSAT. The positive Phase 2 CHOPIN trial results for combination therapy in metastatic uveal melanoma are highly encouraging, suggesting expanded market potential and improved patient outcomes. Furthermore, the initiation of Phase 2 trials for metastatic colorectal cancer and metastatic breast cancer indicates a robust pipeline and strategic expansion into large addressable markets. While R&D and SG&A expenses are increasing, they are aligned with commercial expansion and pipeline development. The share repurchase program signals management's confidence in the company's valuation. These factors collectively point to strong operational momentum and significant future growth potential, making it an attractive investment.

Keywords

Delcath Systems, HEPZATO KIT, CHEMOSAT, Uveal Melanoma, Metastatic Liver Cancer, Interventional Oncology, Drug-Device Combination, Clinical Trials, FDA Approval, Orphan Drug, Melphalan, Immunotherapy, Colorectal Cancer, Breast Cancer, Healthcare Reimbursement, SEC Filing, Biotechnology, Pharmaceuticals, Oncology